Biotech
A Calcium Pill Just Beat Standard Care 76% to 4% — and Switched a Missing Hormone Back On in 91%
BridgeBio's encaleret hit its Phase 3 target in 76% of ADH1 patients vs 4% on standard care, restored PTH in 91%, with an FDA decision set for May 8, 2027.